Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC(neoSCORE Ⅱ)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a Phase 3, prospective, randomized, open-label, multi-center study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for Resectable Squamous Cell NSCLC. This trial will also explore the biomarkers of neoadjuvant immunochemotherapy.
Epistemonikos ID: 97a9248f52b2982b66c45c4d7e4282fb45514d33
First added on: May 13, 2024